Last Updated : May 13, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type Sort descending | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Epclusa | sofosbuvir / velpatasvir | Hepatitis C, chronic | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | ||
Trelegy Ellipta | fluticasone furoate/umeclidinium bromide/vilanterol trifenatate | Asthma, maintenance | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | ||
Xolair | omalizumab | Chronic rhinosinusitis with nasal polyps | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | ||
Nucala | mepolizumab | Asthma, severe eosinophilic (pediatric) | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | ||
Tafinlar and Mekinist | dabrafenib and trametinib | Pediatric glioma with a BRAF V600E | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | ||
Trecondyv | treosulfan | Conditioning treatment prior to stem cell transplantation for acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) (pediatric) | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | ||
Darzalex | daratumumab | Multiple myeloma, eligible for autologous stem cell transplant | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | ||
Victoza | liraglutide | Diabetes Mellitus, Type 2 (pediatric) | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | ||
Keytruda | Pembrolizumab | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | |||
Lynparza | Olaparib | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed |